



Recombinant Influenza Viruses for Vaccines and Gene Therapy

[View U.S. Patent No. 8,715,940 in PDF format.](#)

WARF: P99264US

Inventors: Yoshihiro Kawaoka, Gabriele Neumann

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing a method to efficiently generate fully constructed, artificial influenza virus.

Overview

Influenza viruses show strong potential as vaccine and gene delivery vectors: they do not replicate through DNA intermediates (which may incorporate into the host genome); they elicit strong immune responses; and they exist in a wide range of antigenic variants, allowing repeated immunization and long-term use. However, influenza viruses have proven difficult to manipulate in the laboratory. As negative strand RNA viruses with viral RNA (vRNA) *complementary* to messenger RNA (mRNA), their replication requires a complex unit composed of viral polymerase and other proteins, which both replicates vRNA and transcribes it into mRNA for protein synthesis by the host cell. To generate genetically modified influenza virus, engineered vRNA must be assembled into these replication units, a process that is both laborious and inefficient.

The Invention

UW-Madison researchers have now developed a method to efficiently generate fully constructed, artificial influenza virus. The method involves transforming a host cell with 10 DNA plasmids, each containing a DNA copy of a segment from the influenza viral genome. Nine of the plasmids express proteins needed for viral replication and assembly, while the tenth contains a transgene inserted between an RNA pol I promoter and a terminator, for gene expression.

Applications

- More rapidly generating and studying lethal mutations in viral processes, such as formation, packaging, binding and fusion, which may be useful targets for vaccines
- Should allow development of improved gene therapy vectors because the researchers have also shown they can deliver a transgene without generating active virus in the recipient cell

Key Benefits

- Allows manipulation of the influenza viral genome as DNA, which is more stable and easier to handle than RNA
- System is highly efficient, both in the infection of host cells and the yield of genetically modified virus particles (>10⁴ infectious particles/milliliter).
- Potentially applicable to other viruses, such as paramyxoviruses and rhabdoviruses

Stage of Development

We use cookies on this site to enhance your experience and improve our marketing efforts. By continuing to browse without changing your browser settings to block or delete cookies, you agree to the storing of cookies and related technologies on your device. [See our privacy policy.](#)

OK



WARF
Wisconsin Alumni Research Foundation

| info@warf.org | 608.960.9850

Additional Information

Related Technologies

- [This technology is currently available for licensing for non-human uses only.](#)

Related Intellectual Property

- [View Continuation Patent in PDF format.](#)
- [View Continuation Patent in PDF format.](#)
- [View Continuation Patent in PDF format.](#)

Tech Fields

- [Drug Discovery & Development : Drug production & design](#)

For current licensing status, please contact Jennifer Gottwald at jennifer@warf.org or 608-960-9854

We use cookies on this site to enhance your experience and improve our marketing efforts. By continuing to browse without changing your browser settings to block or delete cookies, you agree to the storing of cookies and related technologies on your device. [See our privacy policy.](#)

OK



WARF
Wisconsin Alumni Research Foundation

| info@warf.org | 608.960.9850